Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

(2016) Anton Pozniak et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2016) David Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?

(2016) Christina M. Wyatt   KIDNEY INTERNATIONAL

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

(2016) Anthony Mills et al.   LANCET INFECTIOUS DISEASES

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

(2016) Marco Vitoria et al.   Journal of the International AIDS Society

Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors

(2015) Gabriel Birkus et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of HIV-1 Resistance to Tenofovir AlafenamideIn Vitro

(2015) Nicolas A. Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate

(2015) Christian Callebaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Epi-TAF for Tenofovir Disoproxil Fumarate?: Table 1.

(2015) Rochelle P. Walensky et al.   CLINICAL INFECTIOUS DISEASES

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

(2014) Rujuta A Bam et al.   ANTIVIRAL THERAPY

Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors

(2014) Rujuta A Bam et al.   ANTIVIRAL THERAPY

Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection

(2014) Emma D. Deeks   DRUGS

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

(2014) M. Markowitz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients

(2014) Samir K. Gupta et al.   PLoS One

Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection

(2013) Emma D. Deeks   DRUGS

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya

(2013) L. Ryom et al.   JOURNAL OF INFECTIOUS DISEASES

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations

(2010) Sonia Rodríguez-Nóvoa et al.   AIDS